Lixte Biotechnology Operating Income Over Time
| LIXT Stock | USD 3.04 0.11 3.49% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Lixte Biotechnology Performance and Lixte Biotechnology Correlation. Is there potential for Biotechnology market expansion? Will Lixte introduce new products? Factors like these will boost the valuation of Lixte Biotechnology. Expected growth trajectory for Lixte significantly influences the price investors are willing to assign. Understanding fair value requires weighing current performance against future potential. All the valuation information about Lixte Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lixte Biotechnology is measured differently than its book value, which is the value of Lixte that is recorded on the company's balance sheet. Investors also form their own opinion of Lixte Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Lixte Biotechnology's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Lixte Biotechnology's market value can be influenced by many factors that don't directly affect Lixte Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Lixte Biotechnology's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lixte Biotechnology represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Lixte Biotechnology's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Operating Income Analysis
Compare Lixte Biotechnology and related stocks such as Kairos Pharma, Lexaria Bioscience Corp, and Allarity Therapeutics Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KAPA | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1.9 M) | (571 K) | (1.7 M) | (2.3 M) | (2.1 M) | (2.2 M) |
| LEXX | (215 K) | (56.9 K) | (76.1 K) | 294.1 K | (1.9 M) | (1.3 M) | (1.9 M) | (6.6 M) | (4.1 M) | (4.1 M) | (5.5 M) | (6.5 M) | (6.5 M) | (5.7 M) | (11.6 M) | (10.5 M) | (9.9 M) |
| ALLR | (81.2 K) | (81.2 K) | (81.2 K) | (81.2 K) | (68.7 K) | (1.4 M) | (4.5 M) | (3.8 M) | (5 M) | (17.6 M) | (8.3 M) | (26.6 M) | (34.5 M) | (17.1 M) | (27.2 M) | (24.5 M) | (23.3 M) |
| CING | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (7.1 M) | (20.7 M) | (17.5 M) | (22.8 M) | (15.6 M) | (14.1 M) | (14.8 M) |
| BCTX | (8.6 K) | (559.6 K) | (290.1 K) | (476.5 K) | (1.9 M) | (2.2 M) | (3.2 M) | (5 M) | (6.3 M) | (4.8 M) | (8.9 M) | (19.4 M) | (31.3 M) | (45.5 M) | (37.7 M) | (34 M) | (32.3 M) |
| PULM | (30 K) | (30 K) | (523 K) | (3.1 M) | (9.1 M) | (23 M) | (24.9 M) | (17.5 M) | (20.3 M) | (20.7 M) | (9.9 M) | (20.2 M) | (18.9 M) | (14.7 M) | (9.8 M) | (8.8 M) | (9.2 M) |
| HOTH | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (2.5 M) | (7.7 M) | (7.3 M) | (14.1 M) | (11.1 M) | (7.7 M) | (8.2 M) | (7.4 M) | (7.8 M) |
| CASI | (20 K) | (4.6 M) | 4.5 M | 5.7 M | 26.2 M | 7.2 M | 9.4 M | (10.8 M) | (26.5 M) | (40 M) | (52.8 M) | (41.5 M) | (26.5 M) | (25.1 M) | (39.6 M) | (35.7 M) | (33.9 M) |
Lixte Biotechnology and related stocks such as Kairos Pharma, Lexaria Bioscience Corp, and Allarity Therapeutics Operating Income description
Operating Income is the amount of profit realized from Lixte Biotechnology operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Lixte Biotechnology Holdings is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Lixte Biotechnology Holdings | LIXT |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 680 East Colorado |
| Exchange | NASDAQ Exchange |
USD 3.04
Additional Tools for Lixte Stock Analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.